Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Action antagonists |
Mechanism SSTR antagonists(Somatostatin receptor antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic breast cancer | Preclinical | Switzerland | 01 Oct 2025 | |
| SSTR2 positive Gastro-Enteropancreatic Neuroendocrine Tumor | Preclinical | Switzerland | 01 Oct 2025 | |
| Colorectal Cancer | Preclinical | Switzerland | 27 Sep 2024 |





